![]() |
|
|
Vol. 290, Issue 1, 413-422, July 1999
Division of Clinical Pharmacology (Y.C., A.J.J.W.) and Pulmonary
Department (J.S.), Vanderbilt University School of Medicine,
Nashville, Tennessee
CYP2D6 is polymorphically distributed so that in poor metabolizers
enzyme activity is missing. The goal of this study was to compare the
pharmacokinetics and pharmacodynamics of codeine with and without
quinidine between Caucasian and Chinese extensive metabolizers of
debrisoquin. Nine Caucasians and eight Chinese subjects received in
random, double blind fashion, on two occasions, codeine 120 mg. with
placebo or with quinidine 100 mg. Pharmacodynamic effects were
determined over 6 h. Codeine-apparent clearance and partial
metabolic clearance by O-demethylation were significantly greater in
the Caucasian than in the Chinese subjects (1939 ± 175 ml/min
versus 1301 ± 193 ml/min, p < .03 and
162.7 ± 36.6 ml/min versus 52.7 ± 12.7 ml/min,
p < .02, respectively). Codeine's respiratory
effects (except on resting ventilation) were significantly greater in
the Caucasian than in the Chinese subjects (p < .05), but no interethnic differences were noted in codeine's effect on
the digit symbol substitution test and pupillary ratio. No morphine or morphine metabolites were detected in plasma when codeine
was coadministered with quinidine. Codeine O-demethylation was
significantly reduced after quinidine in both ethnic groups; however,
the absolute decrease was greater in Caucasians (115.8 ± 25.9 ml/min versus 46.8 ± 10.6 ml/min, respectively,
p < .03). The diminished production of morphine
after quinidine was associated in the Caucasians, but not in the
Chinese, with a marked reduction in codeine's effects
(p < .01). In conclusion, Chinese produce less
morphine from codeine, exhibit reduced sensitivity to that morphine,
and therefore might experience reduced analgesic effect in response to
codeine. In addition, quinidine induced inhibition of codeine
O-demethylation is ethnically dependent with the reduction being
greater in Caucasians.
This article has been cited by other articles:
![]() |
H. S. Smith Opioid Metabolism Mayo Clin. Proc., July 1, 2009; 84(7): 613 - 624. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. M. Roden and C. M. Stein Clopidogrel and the Concept of High-Risk Pharmacokinetics Circulation, April 28, 2009; 119(16): 2127 - 2130. [Full Text] [PDF] |
||||
![]() |
D. M. Roden, R. B. Altman, N. L. Benowitz, D. A. Flockhart, K. M. Giacomini, J. A. Johnson, R. M. Krauss, H. L. McLeod, M. J. Ratain, M. V. Relling, et al. Pharmacogenomics: Challenges and Opportunities. Ann Intern Med, November 21, 2006; 145(10): 749 - 757. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. R Shah Pharmacogenetics in drug regulation: promise, potential and pitfalls Phil Trans R Soc B, August 29, 2005; 360(1460): 1617 - 1638. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Gasche, Y. Daali, M. Fathi, A. Chiappe, S. Cottini, P. Dayer, and J. Desmeules Codeine Intoxication Associated with Ultrarapid CYP2D6 Metabolism N. Engl. J. Med., December 30, 2004; 351(27): 2827 - 2831. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Kim, J. A. Johnson, and H. Derendorf Differences in Drug Pharmacokinetics Between East Asians and Caucasians and the Role of Genetic Polymorphisms J. Clin. Pharmacol., October 1, 2004; 44(10): 1083 - 1105. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. D. Bjornsson, J. A. Wagner, S. R. Donahue, D. Harper, A. Karim, M. S. Khouri, W. R. Murphy, K. Roman, D. Schneck, D. S. Sonnichsen, et al. A Review and Assessment of Potential Sources of Ethnic Differences in Drug Responsiveness J. Clin. Pharmacol., September 1, 2003; 43(9): 943 - 967. [Abstract] [Full Text] [PDF] |
||||